Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sevelamer

- PMLiVE

FDA gives green light to Genzyme’s oral Gaucher drug

Oral therapy Cerdelga is set to complement intravenous Cerezyme

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

- PMLiVE

Sanofi ships synthetic malaria jab

French manufacturer says Gates Foundation-funded venture could widen treatment

- PMLiVE

Sanofi cuts $925m deal for MannKind’s inhaled insulin

French company bolsters diabetes business with Afrezza collaboration

Sanofi reception

Sanofi asks Emcure to sell its cancer drugs in India

Will hand over marketing of Taxotere, Jevtana, Fludara and Fasturtec

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

dengue fever mosquito

Sanofi’s dengue vaccine could debut in 2015

End in sight after 20-year wait for first effective vaccine

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

- PMLiVE

FDA to review Sanofi’s Lantus successor

Decision on company’s next generation insulin Toujeo expected early next year

- PMLiVE

Teva’s chair Philip Frost to step down

He will leave the Israeli pharma company by the end of the year

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links